

# Getting Your Patient Started on ARIKAYCE

## Arikares<sup>®</sup> Support Program Enrollment Form and Patient Information

**ARIKAYCE<sup>®</sup>**  
(amikacin liposome inhalation suspension)  
Limited Population

**Arikares<sup>®</sup>**  
Support Program

**ARIKAYCE Prescription and Arikares<sup>®</sup> Support Program Enrollment Form**

**Fax: 1-800-604-6027 or E-mail: enrollment@arikares.com**  
Please complete all fields on pages 1 and 3 to prevent any delays and include scanned copies of both sides of the patient's insurance card (fields marked with an asterisk [\*] are mandatory/required).

**Questions?**  
Phone: 1-833-ARIKARE  
Alternate Phone: 1-973-437-2376

**PATIENT INFORMATION**

\*Patient First Name: \_\_\_\_\_ \*Patient Last Name: \_\_\_\_\_  
\*DOB: \_\_\_\_\_ \*Gender:  Male  Female  Non-binary  Unknown Last 4 of SSN: \_\_\_\_\_  
\*Physical Address: \_\_\_\_\_  
\*City: \_\_\_\_\_ \*State: \_\_\_\_\_ \*ZIP: \_\_\_\_\_  
\*Mailing Address: \_\_\_\_\_  Same as Physical Address  
\*City: \_\_\_\_\_ \*State: \_\_\_\_\_ \*ZIP: \_\_\_\_\_  
\*Mobile Phone: \_\_\_\_\_ Home Phone: \_\_\_\_\_ E-mail: \_\_\_\_\_  
Preferred Contact Method(s): (check all that apply)  Phone  E-mail  Text  
Preferred Time to Contact:  Morning  Afternoon  Evening  
Preferred Contact Language:  English  Spanish  Other: \_\_\_\_\_  
Authorized Alternate Contact: \_\_\_\_\_  
Alternate Contact Phone: \_\_\_\_\_ Relationship to Patient: \_\_\_\_\_

**Prescription Insurance Information (Please Send a Copy of Insurance Card)**

\*Prescription Coverage Plan Name: \_\_\_\_\_  
Beneficiary/Cardholder: \_\_\_\_\_ Relationship to Cardholder: \_\_\_\_\_  
\*Primary Rx Insurance ID #: \_\_\_\_\_ \*Group #: \_\_\_\_\_  
\*BIN: \_\_\_\_\_ \*PCN: \_\_\_\_\_ \*Phone: \_\_\_\_\_  
\*Primary Rx Plan Type:  Private/Commercial  Medicare Part D  Medicaid  TRICARE  
Secondary Prescription Coverage Plan Name: \_\_\_\_\_  
Beneficiary/Cardholder: \_\_\_\_\_ Relationship to Cardholder: \_\_\_\_\_  
Secondary Rx Insurance ID #: \_\_\_\_\_ Group #: \_\_\_\_\_  
BIN: \_\_\_\_\_ PCN: \_\_\_\_\_ Phone: \_\_\_\_\_  
Secondary Rx Plan Type:  Private/Commercial  Medicare Part D  Medicaid  TRICARE  
**Patient Does Not Have Insurance**

**Patient Authorization Signature**

**Protected Health Information Disclosure Authorization and Consent**—I have read and understand the Protected Health Information Disclosure Authorization and Consent on page 2. By signing below, I authorize the disclosure of my Protected Health Information to Inamed, Inc. and its affiliates for the purposes of enrolling me in the Inamed Patient Support Program and processing of my Health Information as described in the Patient Support Program Enrollment Consent on page 2. By signing below, I agree to enroll in the Inamed Patient Support Program and processing of my Health Information as described in the Patient Support Program Enrollment Consent on page 2.

\*Patient Signature: \_\_\_\_\_ \*Date: \_\_\_\_\_

**Patient Support Program Enrollment Consent**—I have read and understand the Patient Support Program Enrollment Consent on page 2. By signing below, I agree to enroll in the Inamed Patient Support Program and processing of my Health Information as described in the Patient Support Program Enrollment Consent on page 2.

\*Patient Signature: \_\_\_\_\_ \*Date: \_\_\_\_\_

Please see Indication and Important Safety Information for ARIKAYCE, including Boxed Warning, on page 4. Please see accompanying full Prescribing Information. © 2024 Inamed Incorporated. All Rights Reserved. Inamed, ARIKAYCE, and Arikares are trademarks of Inamed Incorporated. All other trademarks are property of their respective owner. PP-ARIK-US-02238

Patient Authorization must be submitted on ENROLL.ARIKARE.COM

Pg 1 of 4

**ARIKAYCE<sup>®</sup>**  
(amikacin liposome inhalation suspension)  
Limited Population

**Arikares<sup>®</sup>**  
Support Program

**ARIKAYCE Prescription and Arikares<sup>®</sup> Support Program Enrollment Form**

**Fax: 1-800-604-6027 or E-mail: enrollment@arikares.com**  
Please complete all fields on pages 1 and 3 to prevent any delays and include scanned copies of both sides of the patient's insurance card (fields marked with an asterisk [\*] are mandatory/required).

**Questions?**  
Phone: 1-833-ARIKARE (1-833-274-5273)  
Alternate Phone: 1-973-437-2376

**HEALTHCARE PROFESSIONAL & PRESCRIPTION INFORMATION**

\*Prescriber First Name: \_\_\_\_\_ \*Prescriber Last Name: \_\_\_\_\_  
\*Practice Name: \_\_\_\_\_ Specialty: \_\_\_\_\_  
\*Address: \_\_\_\_\_ \*City: \_\_\_\_\_ \*State: \_\_\_\_\_ \*ZIP: \_\_\_\_\_  
\*Phone: \_\_\_\_\_ \*Fax: \_\_\_\_\_ \*NPI #: \_\_\_\_\_  
Office Contact Name: \_\_\_\_\_ Office Contact Phone: \_\_\_\_\_  
Office Contact E-mail: \_\_\_\_\_

If Applicable, Check Appropriate Box for Specialty Pharmacy Preference:  
 No Preference  Maxor Specialty Pharmacy  PANTHERx RARE Pharmacy  Amber Specialty Pharmacy  
Please note if ARIKAYCE is being ordered through:  VA  340B entity

**Official Prescription Information**

\*Patient First Name: \_\_\_\_\_ \*Patient Last Name: \_\_\_\_\_ \*DOB: \_\_\_\_\_  
 **Product:** ARIKAYCE<sup>®</sup> (amikacin liposome inhalation suspension) Quantity: 28-Day Supply: 28-Vial Pack (28 Vials of Medication, 4 Aerosol Heads, and 1 Handset) (First Shipment Includes Lantana<sup>®</sup> System)  
Dosing Info: Once-Daily 590 mg/8.4 mL  # of Refills: \_\_\_\_\_

New York prescribers, please submit prescription on an original NY State prescription blank. The prescriber is to comply with his or her state-specific form, fax language, etc. Non-compliance with state-specific requirements could result in outreach to the prescriber.

\*Substitution Permitted?  Yes  No

**Prescriber Certification**

I certify that the above therapy is medically necessary, and that the information provided is accurate to the best of my knowledge. By submitting this form, I certify that I am the prescriber who has prescribed ARIKAYCE to the previously identified patient, that the patient authorized the disclosure of their personal health information to Inamed, that I provided the patient with a description of the Inamed Patient Support Program, and that the patient has given permission to be contacted by Inamed regarding the Inamed Patient Support Program. I authorize the Inamed Patient Support Program to act on my behalf for the purposes of transmitting this prescription to the appropriate pharmacy.

\*Prescriber Signature: \_\_\_\_\_ \*Date: \_\_\_\_\_  
No stamped signatures accepted

Special Instructions:  
 Pre-treatment with inhaled bronchodilator due to history of hyperreactive airway disease

Please see Indication and Important Safety Information for ARIKAYCE, including Boxed Warning, on page 4. Please see accompanying full Prescribing Information. © 2024 Inamed Incorporated. All Rights Reserved. Inamed, ARIKAYCE, and Arikares are trademarks of Inamed Incorporated. All other trademarks are property of their respective owner. PP-ARIK-US-02238

Pg 3 of 4

  
**ARIKAYCE<sup>®</sup>**  
(amikacin liposome  
inhalation suspension)  
Limited Population

**Arikares<sup>®</sup>**  
Support Program

Please see the accompanying full Prescribing Information for ARIKAYCE for information about Limited Population. Please see Indication and Important Safety Information for ARIKAYCE enclosed, including Boxed Warning.

The *Arikares Support Program* is designed to help your patients **get started on ARIKAYCE (amikacin liposome inhalation suspension), become familiar with taking it, and receive support** during their treatment journey.

  
**ARIKAYCE**<sup>®</sup>  
(amikacin liposome  
inhalation suspension)  
**Limited Population**

**Arikares**<sup>®</sup>  
Support Program



### PROGRAM ENROLLMENT

- Complete the *Arikares* Enrollment Form **enclosed** or **download an interactive form** by visiting [ArikaresEnrollmentForm.com](http://ArikaresEnrollmentForm.com)
  - Submit all pages via fax (1-800-604-6027) or e-mail ([enrollment@arikares.com](mailto:enrollment@arikares.com))
- Patient signature on the *Arikares* enrollment form is required to receive full benefits of the program



### PAYER ACCESS EDUCATION

- *Patient Access Lead* is available to provide the most recent publicly available payer-specific information regarding
  - Payer approval process
  - Prior authorization and reauthorization
  - Appeal process



### SHIPMENT COORDINATION

- *Arikares Coordinator* and specialty pharmacy work with the patient to coordinate the shipment of medication
- Specialty pharmacy reviews financial support options with patient



### DEVICE TRAINING

- *Arikares Trainer* can provide one in-office or virtual train-the-trainer to healthcare provider and staff
- *Trainer* conducts voluntary in-home or virtual device training for patient and caregiver(s)



### ONGOING PATIENT SUPPORT

- *Arikares Coordinator* provides office with patient updates and answers patients' device-related questions

Insmed Therapeutic Specialist

*Arikares* Team

Please see the accompanying full Prescribing Information for ARIKAYCE for information about Limited Population. Please see Indication and Important Safety Information for ARIKAYCE enclosed, including Boxed Warning.

### QUESTIONS?

Call the *Arikares Support Program* at 1-833-ARIKARE (1-833-274-5273) or 1-973-437-2376.

# The Arikares Support Program Enrollment Form

The Arikares Support Program Enrollment Form is the first step in prescribing ARIKAYCE and enrolling patients in Arikares. To begin, you need to gather all the relevant information from each of your patients. To avoid delays, please **complete all the mandatory fields** in the Enrollment Form (fields marked with an asterisk [\*]) are required if your patient would like to enroll in Arikares).

**Below you can find an annotated example highlighting what's required from the patient and physician sections.**

Remember to include copies of each patient's insurance card(s) when submitting the Enrollment Form and Prescription (Rx).



## Patient information



- ▶ Ensure patient demographic information is filled out completely

## Prescription insurance information

- ▶ Provide policy and phone numbers
- ▶ Include separate prescription plan (if applicable)

## Patient signature and date required for enrollment in the Arikares Support Program

- ▶ Ensure patients sign both signature areas on their Enrollment Form prior to leaving the office. Patient signatures are required to receive full benefits of the program
- ▶ **Patients must read and understand page 2 of the Enrollment Form prior to signing**

**ARIKAYCE Prescription and Arikares® Support Program Enrollment Form**

Fax: 1-800-604-6027 or E-mail: enrollment@arikares.com  
 Please complete all fields on pages 1 and 3 to prevent any delays and include scanned copies of both sides of the patient's insurance card (fields marked with an asterisk [\*] are mandatory/required).

**Questions?**  
 Phone: 1-833-ARIKARE (1-833-274-5273)  
 Alternate Phone: 1-973-437-2376

---

**PATIENT INFORMATION**

\*Patient First Name: \_\_\_\_\_ \*Patient Last Name: \_\_\_\_\_ \*MI: \_\_\_\_\_  
 \*DOB: \_\_\_\_\_ \*Gender:  Male  Female  Non-binary  Unknown Last 4 of SSN: \_\_\_\_\_  
 \*Physical Address: \_\_\_\_\_  
 \*City: \_\_\_\_\_ \*State: \_\_\_\_\_ \*ZIP: \_\_\_\_\_  
 \*Mailing Address: \_\_\_\_\_  Same as Physical Address  
 \*City: \_\_\_\_\_ \*State: \_\_\_\_\_ \*ZIP: \_\_\_\_\_  
 \*Mobile Phone: \_\_\_\_\_ Home Phone: \_\_\_\_\_ E-mail: \_\_\_\_\_

Preferred Contact Method(s): (check all that apply)  Phone  E-mail  Text  
 Preferred Time to Contact:  Morning  Afternoon  Evening  
 Preferred Contact Language:  English  Spanish  Other: \_\_\_\_\_  
 Authorized Alternate Contact: \_\_\_\_\_  
 Alternate Contact Phone: \_\_\_\_\_ Relationship to Patient: \_\_\_\_\_

**Prescription Insurance Information (Please Send a Copy of Insurance Card)**

\*Prescription Coverage Plan Name: \_\_\_\_\_  
 Beneficiary/Cardholder: \_\_\_\_\_ Relationship to Cardholder: \_\_\_\_\_  
 \*Primary Rx Insurance ID #: \_\_\_\_\_ \*Group #: \_\_\_\_\_  
 \*BIN: \_\_\_\_\_ \*PCN: \_\_\_\_\_ \*Phone: \_\_\_\_\_  
 \*Primary Rx Plan Type:  Private/Commercial  Medicare Part D  Medicaid  TRICARE  Other  
 Secondary Prescription Coverage Plan Name: \_\_\_\_\_  
 Beneficiary/Cardholder: \_\_\_\_\_ Relationship to Cardholder: \_\_\_\_\_  
 Secondary Rx Insurance ID #: \_\_\_\_\_ Group #: \_\_\_\_\_  
 BIN: \_\_\_\_\_ PCN: \_\_\_\_\_ Phone: \_\_\_\_\_  
 Secondary Rx Plan Type:  Private/Commercial  Medicare Part D  Medicaid  TRICARE  Other  
**Patient Does Not Have Insurance**

**Patient Authorization Signature**

**Protected Health Information Disclosure Authorization and Consent**—I have read and understand the Protected Health Information Disclosure Authorization and Consent on page 2. By signing below, I authorize the disclosure of my PHI to the Inmed Patient Support Team as described in the Protected Health Information Disclosure Authorization and Consent on page 2.  
 \*Patient Signature: \_\_\_\_\_ \*Date: \_\_\_\_\_

**Patient Support Program Enrollment Consent**—I have read and understand the Patient Support Program Enrollment Consent on page 2. By signing below, I agree to enroll in the Inmed Patient Support Program and consent to processing of my Health Information as described in the Patient Support Program Enrollment Consent on page 2.  
 \*Patient Signature: \_\_\_\_\_ \*Date: \_\_\_\_\_

Please see Indication and Important Safety Information for ARIKAYCE, including Boxed Warning, on page 4. Please see accompanying full Prescribing Information.  
 © 2024 Inmed Incorporated. All Rights Reserved. Inmed, ARIKAYCE, and Arikares are trademarks of Inmed Incorporated. All other trademarks are property of their respective owner. PP-ARIK-US-02238

Patient Authorization may also be submitted online at [ENROLL.ARIKARES.COM](http://ENROLL.ARIKARES.COM)

Pg 1 of 4



Patient Authorization may also be submitted online at [ENROLL.ARIKARES.COM](http://ENROLL.ARIKARES.COM)

Mandatory/required fields are highlighted here in yellow for reference only.

**Please see the accompanying full Prescribing Information for ARIKAYCE for information about Limited Population. Please see Indication and Important Safety Information for ARIKAYCE enclosed, including Boxed Warning.**

ARIKAYCE Prescription and  
Arikares<sup>®</sup> Support Program  
Enrollment Form



Fax: 1-800-604-6027 or E-mail: enrollment@arikares.com

Please complete all fields on pages 1 and 3 to prevent any delays and include scanned copies of both sides of the patient's insurance card (fields marked with an asterisk [\*] are mandatory/required).



**Questions?**  
Phone: 1-833-ARIKARE (1-833-274-5273)  
Alternate Phone: 1-973-437-2376

**HEALTHCARE PROFESSIONAL & PRESCRIPTION INFORMATION**

\*Prescriber First Name: \_\_\_\_\_ \*Prescriber Last Name: \_\_\_\_\_  
 \*Practice Name: \_\_\_\_\_ Specialty: \_\_\_\_\_  
 \*Address: \_\_\_\_\_ \*City: \_\_\_\_\_ \*State: \_\_\_\_\_ \*ZIP: \_\_\_\_\_  
 \*Phone: \_\_\_\_\_ \*Fax: \_\_\_\_\_ \*NPI #: \_\_\_\_\_  
 Office Contact Name: \_\_\_\_\_ Office Contact Phone: \_\_\_\_\_  
 Office Contact E-mail: \_\_\_\_\_

If Applicable, Check Appropriate Box for Specialty Pharmacy Preference:  
 No Preference  Maxor Specialty Pharmacy  PANTHERx RARE Pharmacy  Amber Specialty Pharmacy  
 Please note if ARIKAYCE is being ordered through:  VA  340B entity

**Rx Official Prescription Information**

\*Patient First Name: \_\_\_\_\_ \*Patient Last Name: \_\_\_\_\_ \*DOB: \_\_\_\_\_  
 \*Product: ARIKAYCE<sup>®</sup> (amikacin liposome inhalation suspension) Quantity: 28-Day Supply: 28-Vial Pack (28 Vials of Medication, 4 Aerosol Heads, and 1 Handset)  
 Dosing Info: Once-Daily 590 mg/8.4 mL (First Shipment Includes Laminar<sup>®</sup> System)  
 \*# of Refills: \_\_\_\_\_

New York prescribers, please submit prescription on an original NY State prescription blank. The prescriber is to comply with his or her state-specific form, fax language, etc. Non-compliance with state-specific requirements could result in outreach to the prescriber.

\*Substitution Permitted?  Yes  No

**Prescriber Certification**

I certify that the above therapy is medically necessary, and that the information provided is accurate to the best of my knowledge. By submitting this form, I certify that I am the prescriber who has prescribed ARIKAYCE to the previously identified patient, that the patient authorized the disclosure of their personal health information to Inmed, that I provided the patient with a description of the Inmed Patient Support Program, and that the patient has given permission to be contacted by Inmed regarding the Inmed Patient Support Program. I authorize the Inmed Patient Support Program to act on my behalf for the purposes of transmitting this prescription to the appropriate pharmacy.

\*Prescriber Signature: \_\_\_\_\_ \*Date: \_\_\_\_\_  
*No stamped signatures accepted*

Special Instructions:  
 Pre-treatment with inhaled bronchodilator due to history of hyperreactive airway disease \_\_\_\_\_

Please see Indication and Important Safety Information for ARIKAYCE, including Boxed Warning, on page 4. Please see accompanying full Prescribing Information.

© 2024 Inmed Incorporated. All Rights Reserved. Inmed, ARIKAYCE, and Arikares are trademarks of Inmed Incorporated. All other trademarks are property of their respective owner. PP-ARIK-US-02238

**Prescribing physician contact information**

- ▶ Please list accurate fax numbers for future communications

**Office contact**

- ▶ Staff member in your office who will communicate with an Arikares Coordinator regarding patient enrollment, their insurance coverage, and their progress

**Prescription information**

- ▶ Complete entire section, including number of refills

**Prescriber signature and date**

- ▶ Required; no stamped signatures accepted

**Special instructions**

- ▶ Include any applicable special instructions (optional)

Mandatory/required fields are highlighted here in yellow for reference only.



**ARIKAYCE**<sup>®</sup>  
(amikacin liposome  
inhalation suspension)

Limited Population

**Arikares**<sup>®</sup>  
Support Program

